Abbott reported a first-quarter GAAP diluted EPS of $0.61 and an adjusted EPS of $1.15, reflecting 6% growth. The company completed its acquisition of Exact Sciences, enhancing its position in the oncology diagnostics market. Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5% and adjusted EPS between $5.38 and $5.58, including dilution from the acquisition. This acquisition adds a high-growth vertical to Abbott's portfolio, supporting its confidence in accelerating growth.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
